

```

! FINDPATTERNS on 'geneseq': * allowing 0 mismatches

1 1 HAEGTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1 2 HSEGTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1 3 HAEGTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1 4 HSEGTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1 January 3

ADO44524 ck: 7606 len: 35 ! Ado44524 Human GLP-1 peptide derivative 8S-
2 HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1:

ADO44525 ck: 3095 len: 37 ! Ado44525 Human GLP-1 peptide derivative 8S-
2 HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1:

ADO44523 ck: 2417 len: 33 ! Ado44523 Human GLP-1 peptide derivative 8S-
2 HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1:

ADO44521 ck: 7528 len: 31 ! Ado44521 Human GLP-1 peptide derivative 8S-
2 HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1:

ADO44532 ck: 7810 len: 35 ! Ado44532 Human GLP-1 peptide derivative 8S-
2 HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1:

ADO44522 ck: 9935 len: 32 ! Ado44522 Human GLP-1 peptide derivative 8S-
2 HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
HSEGTTFTSDVSSYLEGQAQAKEFIAWLVKKG (K) {1, 9} R
1:

Database searched: EMBL, Release 8.0, Released on 4Apr2006, Formatted on 29Apr2006
Total length: 457,216,429
Total length: 2,589,679
Total sequences: 2,721

```

!1AA_SEQUENCE 1.0
 ID ADO44521 standard; peptide; 31 AA.
 AC ADO44521;
 XX
 DT 29-JUL-2004 (first entry)
 XX Human GLP-1 peptide derivative 8S-des36R-GLP1+1KR.
 XX
 KW GLP-1; Glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
 KW antidiabetic; anorectic; insulin secretion.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 Key Location/Qualifiers
 FH Modified-site 31
 PT /note= "C-terminal amide"
 XX WO2004037859-A1.
 XX
 PD 06-MAY-2004.
 XX
 PP 10-OCT-2003; 2003WO-JP013020.
 XX
 PR 11-OCT-2002; 2002JP-00299283.
 XX
 PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
 XX
 PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
 XX
 WPI; 2004-357426/33.
 XX
 PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
 PT peptide, with improved transmucosal absorbability used for the treatment
 PT of diabetes.
 XX
 PS Example 1; SEQ ID NO 12; 48pp; Japanese.
 XX
 CC The invention relates to peptides consisting of a sequence derived from
 CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
 CC and/or substitution of one or more amino acid residues. The GLP-1 derived
 CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
 CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
 CC arginine, arginine amide, lysine, lysine amide or homoserine, and n is 0-
 CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
 CC IV and to trypsin due to the nature of the substitution. The peptides can
 CC be synthesised by standard solid-state peptide synthesis methods. The
 CC peptides can be used in the treatment of diabetes (insulin-dependent or
 CC insulin non-dependent), obesity and excessive appetite. Sequences
 CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
 XX
 SQ Sequence 31 AA;
 SQ
 ADO44521 Length: 31 January 31, 2007 15:59 Type: P Check: 7528 ..

1 HSEGTFPSDV SSYLEBQAAK BFIAMLVKGK R

!AA_SEQUENCE 1.0
 ID ADO44522 standard peptide; 32 AA.
 XX
 AC ADO44522;
 XX
 DT 29-JUL-2004 (First entry)
 XX
 DE Human GLP-1 peptide derivative 8S-de836R-GLP1+2KR.
 XX
 KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
 XX
 KW antidiabetic; anorectic; insulin secretion.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 Key Location/Qualifiers
 FH 32
 FT /note= "C-terminal amide"
 XX PN WO2004037859-A1.
 XX PD 06-MAY-2004.
 XX PF 10-OCT-2003; 2003WO-JP013020.
 XX PR 11-OCT-2002; 2002JP-00299283.
 XX PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
 XX PI Hayashi Y, Makino M, Kouzaiki T, Takeda M, Jomori T;
 XX DR 2004-357426/33.
 XX PT New Glucagon-like peptide 1 derivatives comprising an added C-terminal peptide, with improved transmucosal absorbability used for the treatment of diabetes.
 XX Example 1; SEQ ID NO 13; 48pp; Japanese.
 XX PS PS
 PT
 PT
 PT
 XX
 XX The invention relates to peptides consisting of a sequence derived from glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion and/or substitution of one or more amino acid residues. The GLP-1 derived peptides have an added sequence at the C-terminal of formula Waa-(Xaa)_n-Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is arginine, arginine amide, lysine, lysine amide or homoserine; and n is 0-14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase IV and to trypsin due to the nature of the substitution. The peptides can be synthesised by standard solid-state peptide synthesis methods. The peptides can be used in the treatment of diabetes (insulin-dependent or insulin non-dependent), obesity and excessive appetite. Sequences ADO44511-ADO44534 represent examples of GLP-1 peptide derivatives.
 XX Sequence 32 AA;
 XX SQ ADO44522 Length: 32 January 31, 2007 15:58 Type: P Check: 9935 ..
 1 HSEGGFTTSVD SSYLEGQAAK EPIAMLVKGK KR

!1AA_SEQUENCE 1.0
ID ADO44523 standard; peptide; 33 AA.
XX
AC ADO44523;
XX
DT 29-JUL-2004 (First entry)
XX
DE Human GLP-1 peptide derivative 8S-des36R-GLP1+3KR.
XX
KW GLP-1; Glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX
KW antidiabetic; anorectic; insulin secretion.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 33
FT /note= "C-terminal amide"
XX
PN WO2004037859-A1.
XX
PD 06-MAY-2004.
XX
XX
PF 10-OCT-2003; 2003WO-JP013020.
XX
PR 11-OCT-2002; 2002JP-00299283.
XX
PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX
PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX
DR 2004-357426/33.
XX
PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
PT peptide, with improved transmucosal absorbability used for the treatment
PT of diabetes.
XX
PS Example 1; SEQ ID NO 14; 48pp; Japanese.
XX
The invention relates to peptides consisting of a sequence derived from
CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
CC and/or substitution of one or more amino acid residues. The GLP-1 derived
CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)ⁿ-
CC Ya, where Wa is arginine or lysine; Xaa is arginine or lysine; Ya is
CC arginine, arginine amide, lysine amide or homoserine, and n is 0-
CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
CC IV and to trypsin due to the nature of the substitution. The peptides can
CC be synthesised by standard solid-state peptide synthesis methods. The
CC peptides can be used in the treatment of diabetes (insulin-dependent or
CC insulin non-dependent), obesity and excessive appetite. Sequences
CC ADO44512-ADO44514 represent examples of GLP-1 peptide derivatives.
XX
SQ Sequence 33 AA;
XX
AD044523 Length: 33 January 31, 2007 15:59 Type: P Check: 2417 ..

1 HSEGFTTSDV SSYLGQAAK EFLAWLVKGK KCR

!1AA SEQUENCE 1.0
ID ADO44524 standard; peptide; 35 AA.
XX
AC ADO44524;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human GLP-1 peptide derivative 8S-des36R-GLP1+5KR.
XX
KW GLP-1; Glucagon-like peptide 1; despeptidylpeptidase IV; trypsin;
XX
KW antidiabetic; anorectics; insulin secretion.
XX
OS Homo sapiens.
OS Synthetic.
XX
Key Location/Qualifiers
PH Modified-site 35 /note= "C-terminal amide"
XX PN WO2004037859-A1.
XX PD 06-MAY-2004.
XX PP 10-OCT-2003; 2003WO-JP013020.
XX PR 11-OCT-2002; 2002JP-00299283.
XX PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX DR 2004-357426/33.
XX PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
PT peptide, with improved transmucosal absorbability used for the treatment
PT of diabetes.
XX PS Example 1; SEQ ID NO 15; 48pp; Japanese.
XX
The invention relates to peptides consisting of a sequence derived from
CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
CC and/or substitution of one or more amino acid residues. The GLP-1 derived
CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
CC arginine, arginine amide, lysine, lysine amide or homoserine, and n is 0-
CC 14. The GLP-1 peptide derivatives have tolerance to dispertidylpeptidase
CC IV and to trypsin due to the nature of the substitution. The peptides can
CC be synthesised by standard solid-state peptide synthesis methods. The
CC peptides can be used in the treatment of diabetes (insulin-dependent or
CC insulin non-dependent), obesity and excessive appetite. Sequences
CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX Sequence 35 AA;
XX SQ HSEGTFTSDV SSYLEGQAAK EPIALVKGK KKKKR
1 HSEGTFTSDV SSYLEGQAAK EPIALVKGK KKKKR
ADO44524 Length: 35 January 31, 2007 15:59 Type: P Check: 7606 ..

!NAA_SEQUENCE 1.0
ID ADO44525 standard; peptide; 37 AA.
XX
AC ADO44525;
XX
DT 29-JUL-2004 (first entry)
XX Human GLP-1 peptide derivative 8S-des36R-GLP1+7KR.
XX
KW GLP-1; Glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
KW antidiabetic; anorectic; insulin secretion.
XX
OS Homo sapiens.
OS Synthetic.
XX
Key Location/Qualifiers
FH 37
FT Modified-site
FT /note= "C-terminal amide"
XX WO2004037859-A1.
XX
PD 06-MAY-2004.
XX
PP 10-OCT-2003; 2003WO-JP013020.
XX
PR 11-OCT-2002; 2002JP-00299283.
XX
PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX
PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX
WPI; 2004-357426/33.
XX
PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
PT peptide, with improved transmucosal absorbability used for the treatment
PT of diabetes.
XX
Example 1; SEQ ID NO 16; 48pp; Japanese.
XX
The invention relates to peptides consisting of a sequence derived from
CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
CC and/or substitution of one or more amino acid residues. The GLP-1 derived
CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
CC arginine, arginine amide, lysine, lysine amide or homoserine, and n is 0-
CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
CC IV and to trypsin due to the nature of the substitution. The peptides can
CC be synthesised by standard solid-state peptide synthesis methods. The
CC peptides can be used in the treatment of diabetes (insulin-dependent or
CC insulin non-dependent), obesity and excessive appetite. Sequences
CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX
Sequence 37 AA;
SQ
ADO44525 Length: 37 January 31, 2007 15:59 Type: P Check: 3095 ..
1 HSEGTTFSDV SSYLEQAAK EPIAMLVKGK KKKKKR

!AA_SEQUENCE 1.0
ID ADO44532 standard; peptide; 35 AA.
XX
AC ADO44532;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human GLP-1 peptide derivative 8S26Q34N-deb36R-GLP1-5KR.
XX
KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX
KW antidiabetic; anorectics; insulin secretion.
XX
OS Homo sapiens.
OS Synthetic.
XX
Key Location/Qualifiers
Modified-site 35
FT /note= "C-terminal amide"
XX PN WO2004037859-A1.
XX PD 06-MAY-2004.
XX PF 10-OCT-2003; 2003WO-JP013020.
XX PR 11-OCT-2002; 2002JP-00299283.
XX PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX DR 2004-357426/33.
XX PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
PT peptide, with improved transmucosal absorbability used for the treatment
PT of diabetes.
XX PS Example 1; SEQ ID NO 23; 48pp; Japanese.
XX
The invention relates to peptides consisting of a sequence derived from
glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
and/or substitution of one or more amino acid residues. The GLP-1 derived
peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
arginine, arginine amide, lysine, lysine amide or homoserine; n is 0-
14. The GLP-1 peptide derivatives have tolerance to dipeptidyl peptidase
IV and to trypsin due to the nature of the substitution. The peptides can
be synthesised by standard solid-state peptide synthesis methods. The
peptides can be used in the treatment of diabetes (insulin-dependent or
insulin non-dependent), obesity and excessive appetite. Sequences
ADO44532-AD044534 represent examples of GLP-1 peptide derivatives.

Sequence 35 AA;
SQ

ADO44532 Length: 35 January 31, 2007 15:59 Type: P Check: 7810 .

1 HSSTGTFPSDV SSYLEGGAAQ EFIGAVLNGK RKKKR

```
| FINDPATTERNS onpir.* allowing 0 mismatches
|   1 HAEGETTSVDSSYLEGQAAKEFIAMLVKG (K) {1,9}R
|   2 HSEGTTTSVDSSYLEGQAAKEFIAMLVKG (K) {1,9}R
|   3 HAEGETTSVDSSYLEGQAAKEFIAMLVNG (K) {1,9}R
|   4 HSEGTTTSVDSSYLEGQAAKEFIAMLVNG (K) {1,9}R
```

Databases searched:

NBRF, Release 8.0, Released on 31Dec2004, Formatted on 21Jun2005

Total finds:	0
Total length:	96,216,763
Total sequences:	283,416
CPU time:	06:13:12

```
| FINDPATTERNS on/uniprot.* allowing 0 mismatches
|   1 HSEGTFPSDVSSYLEGAAKEFIAWLVKG (K){1,9}R
|   2 HSEGTFPSDVSSYLEGAAKETFIAWLVKG (K){1,9}R
|   3 HSEGTFPSDVSSYLEGQAQEFIFAWLVNG (K){1,9}R
|   4 HSEGTFPSDVSSYLEGQAQEFIFAWLVNG (K){1,9}R
January 3
```

Databases searched:

UNIPROT, Release 7.2, Released on 7Mar2006, Formatted on 7Mar2006

Total finds:	0
Total length:	925,015,592
Total sequences:	2,849,598
CPU time:	1:01:19.41